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Facilitators and barriers to implementation 
of a pragmatic clinical trial in Aboriginal 
health services
Trials that 
address a 
priority health 
issue, have 
had strong 
health service 
engagement 
and adequate 
local support 
seem more 
likely to 
succeed
 The principles of conducting ethically sound health re-search involving Aboriginal 
and Torres Strait Islander peoples 
have been well documented.1-3 There 
are, however, many challenges to 
implementation of these princi-
ples and negative experiences have 
been reported.4-11 A key element to 
the National Health and Medical 
Research Council (NHMRC) guide-
lines for ethical conduct in Aboriginal 
and Torres Strait Islander health re-
search is the notion of reciprocity — 
that the benefits of the research be 
clearly articulated, negotiated and 
implemented in such a way that it 
will build community capacity.1 In 
the context of clinical trials, this in-
cludes ensuring that studies test in-
terventions in the settings in which 
they will eventually be delivered, 
rather than contrived environments 
that are conducive to easier trial im-
plementation. Such trials are often 
referred to as pragmatic randomised 
controlled trials (PRCTs).12
The Kanyini Guidelines with the 
Adherence Polypill (KGAP) study 
was a PRCT that tested whether 
a polypill-based strategy would 
improve prescriber and patient 
adherence to recommended treat-
ments for cardiovascular disease 
(CVD).13-15 The trial was conducted 
between 2008 and 2012 across five 
Australian states in 20 general prac-
tices, 11 urban, rural and remote 
Aboriginal community-controlled 
health services (ACCHSs) and one 
government-run Indigenous health 
service. Participating services were 
each supported by one to three 
nominated community pharmacies. 
Design features that mimicked real-
life practice included the prescrib-
ing of medicines by treating general 
practitioners, patient copayment 
charges for all study and other med-
icines at standard Pharmaceutical 
Benefits Scheme rates and the 
dispensing through community 
pharmacies. A major challenge to 
trial implementation was attaining 
target recruitment rates; only 623 
of the target 1000 participants were 
randomised.16 This led to a longer 
study duration than anticipated, 
with concomitant budget pressures . 
In this qualitative study, we aimed 
to identify facilitators and barriers to 
trial implementation in the ACCHSs 
and government health service from 
the perspective of providers and trial 
participants. The study forms part of 
a broader trial process evaluation.15
Methods
Fifty-three interviews were con-
ducted with 32 health care providers 
and 21 Aboriginal and Torres Strait 
Islander patients at six ACCHSs and 
the government health service from 
April to December 2012. (Appendix 
1 and Appendix 2). Five ACCHSs 
that were involved in the trial were 
unable to participate due to limited 
capacity at the time when interviews 
were being conducted. Participants 
were recruited purposively to yield 
a maximum variation sample based 
on location, age, sex, ethnicity, pres-
ence of CVD, and medication for pa-
tients, and location and profession 
for providers. 
Interviews were conducted at the 
conclusion of the trial as part of 
the overall process evaluation and 
included exploration of experiences 
regarding trial implementation. 
Interview guides were developed 
and iteratively revised to explore 
themes and issues emerging from 
earlier interviews. A team of 
Abstract
Objective: To identify facilitators and barriers to clinical trial 
implementation in Aboriginal health services.
Design: Indepth interview study with thematic analysis.
Setting: Six Aboriginal community-controlled health services and one 
government-run service involved in the Kanyini Guidelines Adherence with 
the Polypill (KGAP) study, a pragmatic randomised controlled trial that 
aimed to improve adherence to indicated drug treatments for people at high 
risk of cardiovascular disease.
Participants: 32 health care providers and 21 Aboriginal and Torres Strait 
Islander patients.
Results: A fundamental enabler was that participants considered the 
research to be governed and endorsed by the local health service. That 
the research was perceived to address a health priority for communities 
was also highly motivating for both providers and patients. Enlisting the 
support of Aboriginal and Torres Strait Islander staff champions who were 
visible to the community as the main source of information about the trial 
was particularly important. The major implementation barrier for staff 
was balancing their service delivery roles with adherence to often highly 
demanding trial-related procedures. This was partially alleviated by the 
research team’s provision of onsite support and attempts to make trial 
processes more streamlined. Although more intensive support was highly 
desired, there were usually insufficient resources to provide this. 
Conclusion: Despite strong community and health service support, major 
investments in time and resources are needed to ensure successful 
implementation and minimal disruption to already overstretched, routine 
services. Trial budgets will necessarily be inflated as a result. Funding 
agencies need to consider these additional resource demands when 
supporting trials of a similar nature.
Research
25MJA 203 (1)  ·  6 July 2015
seven researchers, including three 
Aboriginal researchers, from a range 
of disciplinary backgrounds (health 
economics, pharmacy, nursing and 
public health) who were not involved 
in the implementation of the trial 
conducted the interviews. Most 
interviews were conducted face-to-
face, with a small number conducted 
by telephone for logistic reasons. 
Interviews were professionally tran-
scribed and coded by two research-
ers (H L and L M) using NVivo 9 (QSR 
International). Twelve transcripts 
were selected (six patients and six 
health care providers — pharma-
cists, GPs, nurses and Aboriginal 
health workers [AHWs]) and were 
coded independently by the two 
researchers. These researchers iden-
tified the major themes arising from 
these 12 interviews and developed 
an initial coding framework. Insights 
gained by the research team about 
the context of the interviews and the 
local setting were documented and 
used to aid interpretation. The cod-
ing framework was then discussed 
and refined by a multidisciplinary 
group comprising the study investi-
gators and the interview team. This 
included two ACCHS clinicians who 
were site principal investigators on 
the trial. The two researchers then 
coded the remaining interviews 
and made minor, iterative changes 
to code definitions. 
For this study, we analysed codes 
specifically relating to issues relat-
ing to trial implementation. The ran-
domised controlled trial, including 
its process evaluation, was approved 
by seven regional human research 
ethics committees, including one 
Aboriginal-specific committee. All 
participants who contributed data 
were provided a description of the 
study by the interviewer and given 
the opportunity to discuss any 
concerns before obtaining written 
consent.
Results
Four principal themes relating to bar-
riers and facilitators for trial imple-
mentation were derived. Appendix 3 
contains additional quotes that fur-
ther illustrate the findings. 
Health service governance of 
research
Ensuring community representation 
in governance of the research was a 
dominant issue. ACCHSs were in-
vited to participate through initial 
discussions with senior management 
and governing boards. Formal mem-
oranda of understanding (MOUs) 
with the coordinating research insti-
tutes were established. Amendments 
were made to the standard Medicines 
Australia clinical trial agreement to 
include intellectual property rights of 
ACCHSs and the roles and responsi-
bilities associated with data custodi-
anship. The discussions associated 
with setting up these agreements 
were critical in establishing mutual 
roles and responsibilities, data gov-
ernance, capacity building plans and 
establishment of funding arrange-
ments. One participant referred to 
the MOU as being a “landmark docu-
ment” (GP 23, urban service).
In some instances, these agreements 
were facilitated by local governance 
processes. An AHW at an urban 
ACCHS described how previous 
negative experiences with external 
researchers prompted the establish-
ment of a local research committee 
that would scrutinise external organ-
isations’ research proposals:
In the past, the research that’s 
been conducted has left some 
scars … what has helped has 
been being more organised 
about having our own research 
agenda … so if you want to do 
research [with us then] this is 
what’s important to us. (AHW 
47, urban service)
Motivation to participate
An expectation that the intervention 
could tangibly address an important 
health issue was extremely important 
for both patients and providers:
When you see people that are 
dying around you that are 
the same age as you and even 
younger, it’s all to do with 
health that they died not taking 
medication. Maybe if they were 
given the one pill instead of tak-
ing half a dozen they might be 
still here today. (Patient 4, urban 
service)
Several participating services 
had been involved in the Kanyini 
Vascular Collaboration before the 
trial and many staff were aware of 
the treatment gaps documented in 
the collaboration’s audit of patient 
records.14 Consequently, there was 
strong support from health care pro-
viders for strategies to address these 
gaps.
Effectively communicating the need 
to address these gaps to the commun-
ity was particularly important. At one 
urban ACCHS this was done through 
a community forum and launch of 
the trial. 
A related facilitator of participation 
was the role played by Aboriginal 
staff champions. These staff were 
often the initial point of contact for 
participants seeking information and 
were also referred to by other staff. 
One AHW discussed her role: 
At first it was hard to commu-
nicate with them. But once it got 
mentioned once, twice, maybe 
three times what was in the 
tablet, what the benefits would 
be it started sinking into their 
brains then. (AHW 32, urban 
service)
Balancing service delivery and 
research requirements
An important aspect of the research 
was to incorporate the intervention 
into usual service delivery. Efforts to 
streamline the intervention included 
the prescribing and dispensing of the 
polypill within existing software 
platforms, timing pathology tests to 
coincide with scheduled visits and re-
cruiting community pharmacies that 
were accessible to the participating 
sites. Despite these efforts to integrate 
the intervention into routine care 
processes, some GPs felt it created 
“confusion in their management” and 
“confusion about what they were on 
when they went into hospital”.
Some providers indicated challenges 
balancing trial operations with exist-
ing workloads. This manifested 
differently in urban and remote set-
tings. For example, in urban settings, 
transport services were enlisted to 
facilitate study visits and access to 
medicines, potentially leading to 
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limited transport availability for non-
trial patients. In remote settings, fly-
in fly-out doctors provided services 
to highly mobile populations. This 
created substantial challenges for 
clinic staff to coordinate follow-up 
study visits. One GP felt that the trial 
was more suited to urban ACCHSs: 
You cannot compare it to an 
AMS [Aboriginal Medical 
Service] in Sydney … because 
we are serving about 200 000 
square kilometres at this AMS. 
… our patients might come into 
town but they could be based 
500 kilometres away … and it’s 
a very transient place for many 
of our patients. (GP 40, remote 
service)
Such logistic challenges inevitably 
resulted in delays in recruitment and 
follow-up. To alleviate these chal-
lenges the study team committed 
additional unbudgeted resources to 
support trial sites. 
Research capacity-building 
challenges
A core study objective was to build 
health service research capacity 
through involvement of staff in the 
clinical trial. Most of those inter-
viewed considered trial participa-
tion to be a positive experience, with 
many staff members describing en-
hancement of clinical skills, increased 
awareness of clinical trial processes, 
and deeper collaborations between 
the health service and pharmacies.
A key capacity-building initiative 
was the creation of local Indigenous 
research fellow (IRF) positions to per-
form trial coordinator duties. In prac-
tice, however, recruitment of suitably 
trained individuals was challenging 
and only four positions were filled. 
The idea was that we were 
going to have an [IRF] is a great 
idea, but it just turned that we 
didn’t really have anyone that 
took it on with a passion … [The 
role] is quite complicated … (GP 
3, urban service)
Moreover, like all clinical staff, IRFs 
frequently had competing responsi-
bilities, and found it difficult to bal-
ance their research role with service 
delivery. This led to staff turnover 
in the early part of the study, which 
affected the trial conduct. Overall, 
most trial sites commented that 
additional on-site support from 
research institute staff would have 
been beneficial. This was easier to 
provide at those sites located closer to 
the coordinating research institutes, 
and those sites tended to manage the 
trial with fewer challenges.
Discussion
This study examined the often-
overlooked views and experiences 
of patients and health care provid-
ers from Aboriginal health services 
participating in a clinical trial. The 
key facilitators of participation were 
the interrelated factors of research 
governance, patient and provider per-
ception of the need for this research, 
deployment of effective strategies for 
communication to the community at 
large, and enlisting the support of 
Aboriginal staff champions. These 
facilitators were tempered by several 
challenges related to adequate inte-
gration of the intervention strategy 
into routine care processes, large 
competing demands with routine 
service delivery, and only partially 
successful attempts at building local 
research capacity. These challenges 
manifested differently due to the 
highly diverse settings in which the 
participating services operated.
In Australia, several Indigenous 
health RCTs have been successfully 
conducted through established health 
service–researcher partnerships, par-
ticularly in the area of child health.17-19 
Many have experienced challenges 
in meeting recruitment targets and 
implementing the trials as originally 
conceived. Occasionally, trials have 
had to be abandoned altogether due 
to insurmountable constraints.20 Our 
findings help determine the factors 
that both hinder and promote suc-
cessful conduct of such trials. The 
integration of complex trial proto-
cols that are not supported by senior 
management into underresourced 
health service settings is a recipe for 
implementation failure. Conversely, 
trials that address a priority health 
issue, have had strong health service 
engagement and adequate local sup-
port seem more likely to succeed.
The study was an indepth explora-
tion of issues from a sample that was 
not necessarily representative of all 
participants and providers in the 
trial. Fewer interviews were done in 
remote sites, and staff who had left 
the service or participants who had 
withdrawn by the end of the study 
were not interviewed.
Although this study was based on a 
PRCT, such a design will not always 
be feasible nor acceptable. Alternative 
designs, such as stepped wedge trials 
and cluster RCTs of health service 
interventions, have been successfully 
implemented in collaboration with 
ACCHSs.21,22 Other designs, such as 
crossover studies, interrupted time 
series analyses and propensity score 
matching, are also practical and often 
cheaper to implement. Use of auto-
mated de-identified data extraction 
and opt-out consent processes can 
considerably reduce data collection 
burden and reduce demands on 
Aboriginal health services.22 There 
is also much to be gained from obser-
vational studies, in which routinely 
collected clinical audits can inform 
the evidence base about effective 
health service strategies.14,22-27
Although community participation 
in prioritising the research ques-
tion is of fundamental importance, 
substantial research infrastructure 
investment in health services is 
of equal importance. Aboriginal 
governance and leadership of the 
research agenda must be in place, and 
there are now good examples of how 
large-scale research can incorporate 
this from the outset.28,29 Associated 
with this is clear articulation of the 
resource implications associated with 
participation and ensuring there is 
adequate recognition of this within 
study budgets. The model for capa-
city building had mixed success, 
mainly due to the excessive and com-
peting demands on individuals and 
limited existing research capacity; 
novel models to increase research 
capacity are needed.
There is clearly a need for more 
interventional studies to build the 
evidence base of what works in 
Aboriginal health service settings.23,30 
It is important that research fund-
ing bodies recognise the factors 
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highlighted in this study in their 
grant schemes. The overall $5 mil-
lion (around $8000 per randomised 
patient) spent on the Kanyini GAP 
trial was several times higher than 
the amount originally granted and 
multiple additional funding appli-
cations were required. Although 
guiding statements on appropriate 
ethical conduct of research involving 
Aboriginal and Torres Strait Islander 
peoples acknowledge these issues, 
project-specific funding schemes 
tend not to recognise the impor-
tance of long-term investments in 
research capacity building, beyond 
what is immediately required to 
complete the project.1,2 In addition to 
non-project specific schemes, such as 
the NHMRC Centres for Research 
Excellence, project-specific load-
ings for research conducted in col-
laboration with already overstretched 
Aboriginal and Torres Strait Islander 
health services ought to be consid-
ered to support local research capa-
city building and establishing the 
governance arrangements needed 
to ensure community support. Such 
investments would build the evi-
dence base on models associated with 
success and strengthen the applica-
tion of reciprocity in the conduct of 
Aboriginal and Torres Strait Islander 
research.
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